Prostatron receives panel go-ahead
This article was originally published in Clinica
EDAP International's Prostatron was unanimously recommended for approval for the treatment of benign prostatic hypertrophy by an FDA panel on October 2Oth. The gastroenterology and urology devices advisory committee indicated that post-marketing follow-up should be performed on 100 patients for five years after surgery to ensure that no chronic complications develop. EDAP has the option of performing the extended follow-up on patients who were part of the clinical trials or on new patients.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.